Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

The new line of credit could ease pressure on the money-losing vaccine maker as it tries to chart its post-pandemic future.

Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine franchise from three to up to six approved products b ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna (MRNA) announced program and financial updates at its Analyst Day event. The updates include mRNA pipeline progress and a three-year plan ...

The company said, “Since 2022, Moderna (MRNA) has streamlined its production sites into a global manufacturing network ready for new launches and ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.